Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.58
+0.45 (6.31%)
Sep 8, 2026, 1:16 PM EDT - Market open
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $273.31 million as of September 8, 2026. Its market cap has increased by 45.32% in one year.
Market Cap
273.31M
Enterprise Value
98.85M
1-Year Change
45.32%
Ranking
Category
Stock Price
$7.58
ChartMarket Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has increased from $251.01M to $273.31M, an increase of 8.88%. That is a compound annual growth rate of 1.77%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 8, 2026 | 273.31M | -25.86% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
| Oct 29, 2021 | 251.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Surrozen | 267.51M |
| Anavex Life Sciences | 265.11M |
| Whitehawk Therapeutics | 262.24M |
| Niagen Bioscience | 251.36M |
| NervGen Pharma | 250.53M |
| YD Bio | 248.93M |
| Veraxa Biotech AG | 248.88M |
| Neumora Therapeutics | 246.14M |